Drug intelligence / Profile preview

cci-001

Development stage: Phase 1
Lead developer: PharmaMatrix Holdings
Modality: Small Molecules
Administration: Intravenous

Overview

CCI-001 is a novel colchicine derivative that binds to tubulin, a component of microtubule polymers essential for cellular processes, particularly cell division and mitosis. It has demonstrated stronger binding to β-III tubulin, a tubulin subtype overexpressed in many cancers. Initially developed by University of Alberta, it is now being developed by PharmaMatrix Holdings Ltd.

Other names: beta tubulin polymerization inhibitor CCI-001

Targets

TUBB3 (Tubulin beta-3 chain)

Beyond the preview

Go deeper on cci-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cci-001.

Explore the full profile